The Sleep Disorders Channel is supported through educational grants from Alkermes and Takeda.
VJNeurology is an independent medical education platform. Channel supporters have no influence over the production of content.
Sleep Europe 2026 | Oveporexton approved for narcolepsy type 1: safety and what to expect in first weeks of treatment
Lucie Barateau, MD, PhD, Gui-de-Chauliac Hospital, CHU Montpellier, Montpellier, France, discusses the safety profile of oveporexton, an orexin receptor 2 (OX2R) agonist approved in the US for the treatment of narcolepsy type 1 (NT1) in adults. Dr Barateau explains that oveporexton is safe and well tolerated, with insomnia and frequent urination being the main side effects. These effects are moderate and transient, resolving within days to weeks, and are outweighed by the benefits of treatment. This interview took place at Sleep Europe 2026 in Maastricht, the Netherlands.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
